

FORM 3

**UNITED STATES SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C. 20549**

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response...	0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person * ROSENWALD LINDSAY A MD (Last) (First) (Middle) C/O CB PHARMA ACQUISITION CORP., 24 NEW ENGLAND EXECUTIVE PARK, SUITE 105 (Street) BURLINGTON, MA 01803 (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 12/12/2014	3. Issuer Name and Ticker or Trading Symbol CB Pharma Acquisition Corp. [CNLM]	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner <input checked="" type="checkbox"/> Officer (give title below) <input type="checkbox"/> Other (specify below) Co-Chairman and CEO	5. If Amendment, Date Original Filed(Month/Day/Year)
		6. Individual or Joint/Group Filing(Check Applicable Line) <input type="checkbox"/> Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person	

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares	1,385,000 (1)	I	by Coronado Biosciences, Inc. (2)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Redeemable Warrants	(3)	(4)	Ordinary Shares	265,000 (1)	\$ 11.5	I	by Coronado Biosciences, Inc. (2)
Right to Receive Ordinary Shares	(5)	(6)	Ordinary Shares	265,000 (1)	\$ (5)	I	by Coronado Biosciences, Inc. (2)

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
ROSENWALD LINDSAY A MD C/O CB PHARMA ACQUISITION CORP. 24 NEW ENGLAND EXECUTIVE PARK, SUITE 105 BURLINGTON, MA 01803	X	X	Co-Chairman and CEO	

CORONADO BIOSCIENCES INC 24 NEW ENGLAND EXECUTIVE PARK BURLINGTON, MA 01803		X		
---	--	---	--	--

Signatures

/s/ Lindsay A. Rosenwald		12/12/2014
<small>**Signature of Reporting Person</small>		<small>Date</small>

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Includes securities underlying 265,000 units of the Issuer to be purchased by Coronado Biosciences, Inc. which Coronado Biosciences, Inc. irrevocably committed to purchase prior to the effective date of the registration statement relating to the issuer's initial public offering ("IPO"). Each unit ("Unit") consists of one ordinary share, one right ("Right") to receive one-tenth of one ordinary share upon (1) consummation of the Issuer's initial business combination, and one redeemable warrant ("Warrant") to purchase one half of one ordinary share upon the later of the consummation of the Issuer's initial business combination and 12 months from the effective date of the registration statement relating to the IPO. The purchase is being made on a private placement basis and will be consummated simultaneously with the consummation of the Issuer's IPO.

(2) Mr. Rosenwald is the Chairman, President and Chief Executive Officer of Coronado Biosciences, Inc., and as such, controls the voting and disposition of such shares. Mr. Rosenwald disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that Mr. Rosenwald is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.

(3) The warrants will become exercisable on the later of the completion of an initial business combination and 12 months from the effective date of the registration statement relating to the Issuer's IPO.

(4) The warrants shall expire five years after the completion of an initial business combination, or earlier upon redemption.

(5) Each Right entitles the holder to receive one-tenth (1/10) of one of the Issuer's ordinary shares upon consummation of the Issuer's initial business combination.

(6) If the Issuer fails to consummate an initial business combination within eighteen (18) months from the closing of the Issuer's IPO, the Issuer will be dissolved and the Rights will expire worthless.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.